NEW ORLEANS – Data from much-anticipated studies were revealed at Sunday’s plenary session at the American Society of Hematology’s 55th annual meeting. One was the head-to-head comparison of Genentech Inc./Roche AG’s Gazyva (obinutuzumab/GA101) with Rituxan (rituximab, Biogen Idec.) for the treatment of chronic lymphocytic leukemia (CLL).